Literature DB >> 7693966

Conditional infectivity of a human immunodeficiency virus matrix domain deletion mutant.

C T Wang1, Y Zhang, J McDermott, E Barklis.   

Abstract

We constructed a human immunodeficiency virus (HIV) matrix (MA) deletion mutant by deletion of about 80% of the HIV type 1 Gag MA domain but retaining myristylation and proteolytic processing signals. The effects of this deletion matrix (dl.MA) mutant on HIV particle assembly, processing, and infectivity were analyzed. Surprisingly, the dl.MA mutant still could assemble and process virus particles, had a wild-type (wt) retrovirus particle density, and possessed wt reverse transcriptase activity. RNase protection experiments showed that dl.MA mutant particles preferentially packaged viral genomic RNA. When both mutant and wt particles were pseudotyped with an amphotropic murine leukemia virus envelope protein, mutant infectivity was about 10% of wt level. In contrast, infectivity of the dl.MA mutant was 1,000-fold less than that of wild-type when mutant and wt particles were pseudotyped with the HIV envelope protein. Protein analyses of pseudotyped virions indicated that there were no major differences between mutant and wt viruses in the efficiency of amphotropic murine leukemia virus envelope protein incorporation. In contrast, there was a reduction in the amount of mutant particle-associated HIV envelope protein gp120. Our results suggest that an intact HIV matrix domain is not absolutely required for reverse transcription, nuclear localization, or integration but is necessary for appropriate HIV envelope protein function.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7693966      PMCID: PMC238168     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

1.  Mutations of RNA and protein sequences involved in human immunodeficiency virus type 1 packaging result in production of noninfectious virus.

Authors:  A Aldovini; R A Young
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

2.  Detection of specific sequences among DNA fragments separated by gel electrophoresis.

Authors:  E M Southern
Journal:  J Mol Biol       Date:  1975-11-05       Impact factor: 5.469

3.  Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1.

Authors:  H G Göttlinger; J G Sodroski; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

4.  A nucleoprotein complex mediates the integration of retroviral DNA.

Authors:  B Bowerman; P O Brown; J M Bishop; H E Varmus
Journal:  Genes Dev       Date:  1989-04       Impact factor: 11.361

5.  Characterization of Moloney murine leukemia virus mutants with single-amino-acid substitutions in the Cys-His box of the nucleocapsid protein.

Authors:  C Méric; S P Goff
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 7.  Assembly of animal viruses at cellular membranes.

Authors:  E B Stephens; R W Compans
Journal:  Annu Rev Microbiol       Date:  1988       Impact factor: 15.500

8.  A unique human immunodeficiency virus culture secreting soluble gp160.

Authors:  V S Kalyanaraman; R Pal; R C Gallo; M G Sarngadharan
Journal:  AIDS Res Hum Retroviruses       Date:  1988-10       Impact factor: 2.205

9.  Assembly and composition of intracellular particles formed by Moloney murine leukemia virus.

Authors:  M Hansen; L Jelinek; R S Jones; J Stegeman-Olsen; E Barklis
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

10.  Identification of a sequence required for efficient packaging of human immunodeficiency virus type 1 RNA into virions.

Authors:  A Lever; H Gottlinger; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

View more
  67 in total

1.  Binding of human immunodeficiency virus type 1 Gag to membrane: role of the matrix amino terminus.

Authors:  A Ono; E O Freed
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  Reversion of a human immunodeficiency virus type 1 matrix mutation affecting Gag membrane binding, endogenous reverse transcriptase activity, and virus infectivity.

Authors:  R E Kiernan; A Ono; E O Freed
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

3.  Nef enhances human immunodeficiency virus type 1 infectivity in the absence of matrix.

Authors:  Tatyana Dorfman; Elena Popova; Massimo Pizzato; Heinrich G Göttlinger
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

4.  Tail-interacting protein TIP47 is a connector between Gag and Env and is required for Env incorporation into HIV-1 virions.

Authors:  Sandra Lopez-Vergès; Grégory Camus; Guillaume Blot; Roxane Beauvoir; Richard Benarous; Clarisse Berlioz-Torrent
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-26       Impact factor: 11.205

5.  Analysis of human immunodeficiency virus matrix domain replacements.

Authors:  Isabel Scholz; Amelia Still; Tenzin Choesang Dhenub; Kelsey Coday; Mike Webb; Eric Barklis
Journal:  Virology       Date:  2007-11-08       Impact factor: 3.616

6.  Foreign glycoproteins can be actively recruited to virus assembly sites during pseudotyping.

Authors:  Rebecca L Jorgenson; Volker M Vogt; Marc C Johnson
Journal:  J Virol       Date:  2009-02-18       Impact factor: 5.103

7.  Lipid biosensor interactions with wild type and matrix deletion HIV-1 Gag proteins.

Authors:  Eric Barklis; August O Staubus; Andrew Mack; Logan Harper; Robin Lid Barklis; Ayna Alfadhli
Journal:  Virology       Date:  2018-03-15       Impact factor: 3.616

8.  Analysis of HIV-1 Matrix-Envelope Cytoplasmic Tail Interactions.

Authors:  Ayna Alfadhli; August O Staubus; Philip R Tedbury; Mariia Novikova; Eric O Freed; Eric Barklis
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

9.  Analysis of human immunodeficiency virus type 1 matrix binding to membranes and nucleic acids.

Authors:  Ayna Alfadhli; Amelia Still; Eric Barklis
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

10.  Human immunodeficiency virus type 2 glycoprotein enhancement of particle budding: role of the cytoplasmic domain.

Authors:  G D Ritter; G Yamshchikov; S J Cohen; M J Mulligan
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.